Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 80/100

Failure Rate

100.0%

2 terminated/withdrawn out of 2 trials

Success Rate

0.0%

-86.5% vs industry average

Late-Stage Pipeline

100%

2 trials in Phase 3/4

Results Transparency

0%

0 of 0 completed trials have results

Key Signals

Enrollment Performance

Analytics

Phase 4
1(50.0%)
Phase 3
1(50.0%)
2Total
Phase 4(1)
Phase 3(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (2)

Showing 2 of 2 trials
NCT04522466Phase 3Terminated

Evaluation of the Pharmacokinetics and Pharmacodynamics of Hydroxychloroquine in COVID-19 Intensive Care Unit Patients

Role: collaborator

NCT04520620Phase 4Withdrawn

Concentration-effect Relationship of Enoxaparin for Thromboembolic Prevention

Role: collaborator

All 2 trials loaded